By: Adam Feuerstein | 02/18/14 - 01:53 PM ESTPrana Biotechnology (PRAN) had one goal Tuesday: Mine deep into the phase II study of its Huntington's disease drug PBT2 to find anything positive to report. A single, positive data point -- even in a study overwhelmingly negative -- would be enough to claim victory and justify moving PBT2 into a phase III study.
Dr. Rudy Tanzi (@RudyTanzi) February 18, 2014"Our drug." Tanzi must be tweeting as a Prana employee with a financial stake in the outcome of PBT2. An employee of Harvard Medical School would have to disclose his financial conflict of interest, at a minimum. And I'm not sure many Harvard professors would find it appropriate to tweet about clinical trial data that's disclosed only in a corporate press release and had not been peer reviewed, published or presented at a medical meeting.
This is the second time PBT2 has improved the cognitive domain of executive function -first in 2008 in Alzheimer's and now in Huntington's. Dr. Rudy Tanzi (@RudyTanzi) February 18, 2014Tanzi must have read my story explaining how the PBT2 study in Huntington's disease failed despite the rosy headline. In response, he tweeted:
@adamfeuerstein seems set on seeing PBT2 fail in his biased blogs. PBT2 SIGNIFICANTLY improved cognition in pre-specified HD patients! #Spin Dr. Rudy Tanzi (@RudyTanzi) February 18, 2014At which point, Tanzi and I got into a fun Twitter spat:
. @RudyTanzi please save the spin for your analysts and gullible investors. PBT2 failed HD. Disgraceful you'd argue otherwise. $PRAN Adam Feuerstein (@adamfeuerstein) February 18, 2014Unlike Tanzi, I neither went to Harvard or co-wrote a book with Deepak Chopra but I do know when negative clinical study data is being spun:
. @RudyTanzi Trail B was single cognitive measure of 8 that passed -- and barely so. Desperation isn't a good look for you. $PRAN Adam Feuerstein (@adamfeuerstein) February 18, 2014I was curious about Tanzi's financial conflict relating to Prana, so I asked him to explain:
Question for @RudyTanzi - Do you have financial disclosure with respect to $PRAN? Adam Feuerstein (@adamfeuerstein) February 18, 2014His reply didn't answer my question:
@adamfeuerstein I simply state publicly available scientific FACTS about the clinical trial of PBT2 in Huntington's disease. And you? Dr. Rudy Tanzi (@RudyTanzi) February 18, 2014Facts? Prana issued a press release! So I tried again:
@RudyTanzi Thats a non-response to my question. I asked you to disclose your financial connection to $PRAN. Adam Feuerstein (@adamfeuerstein) February 18, 2014I'm still waiting for Tanzi's response.
09/22/14 - 07:48 PM EDT
09/22/14 - 08:59 AM EDT
09/19/14 - 12:05 PM EDT
09/16/14 - 01:04 PM EDT
09/15/14 - 10:19 AM EDT
09/23/14 - 10:39 AM EDT
09/22/14 - 10:28 AM EDT
09/22/14 - 09:15 AM EDT
09/21/14 - 15:39 PM EDT
09/20/14 - 14:16 PM EDT
Access the tool that DOMINATES the Russell 2000 and the S&P 500.